Compare peptides
Put two entries side by side — evidence, mechanism, risks, and community claims.
Liraglutide
Clinical
Compounded / restricted
Summary
Once-daily GLP-1 receptor agonist peptide with FDA-approved branded products for type 2 diabetes and chronic weight management; research vials are not those products.
Categories
Metabolic & Body Comp
Mechanism
GLP-1 receptor agonism: enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central and peripheral pathways.
Half-life
~13 hours (acylated analog)
Routes
Subcutaneous injection
Legal / access
FDA-approved branded products exist. Research peptides are not approved drugs and are not interchangeable with Victoza/Saxenda.
Key risks
- Nausea, vomiting, GI effects
- Gallbladder events
- Rare pancreatitis signal
- Thyroid C-cell warnings (rodent; boxed warning class)
Common claims
- Appetite control
- Glycemic support
- Daily GLP-1 alternative to weekly agents
Select peptide B